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Abstract 
Neuroinvasive astrovirus (VA1-HMO-C) is an emerging life-threatening infection in 
immunocompromised hosts. We describe an 8-month-old child who died of VA1/HMO-C encephalitis 
following bone marrow transplantation. The diagnosis was only made post-mortem using RNA deep 
sequencing of the brain. Repeat analysis of the post-mortem brain tissue using PCR specific primers 
for VA1/HMO-C was positive. Astrovirus VA1/HMO-C should be included in the evaluation of patients 
with similar encephalitis. 
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Introduction 
Encephalitis in immunocompromised patients is a diagnostic challenge as the aetiology of the 
global brain dysfunction varies depending on the timing, nature and intensity of immunosuppression. 
The classical clinical features, laboratory findings and cerebrospinal fluid (CSF) pleocytosis may be 
lacking in these patients. (1). Moreover, encephalitis remains unexplained in up to 60% of patients 
despite a comprehensive list of microbiological evaluation with cultures and molecular techniques 
using real time polymerase chain reaction (PCR) for viruses, bacteria, parasites and fungi.(2, 3)  
Deep sequencing can be used as a non-selective method for pathogen discovery and has 
been increasingly used as a diagnostic tool to investigate causes of encephalitis in 
immunocompromised patients.  Sequencing of mRNA is one such approach and is widely used in 
transcriptome analysis but can also be used to detect mRNA from microorganisms. This technique 
involves the isolation of messenger RNA from a clinical sample which following amplification of 
synthesised cDNA. The messenger RNA is analysed using next generation sequencing technology 
that allows for unbiased and sensitive identification of transcripts present. Subsequent bioinformatic 
analysis enables the subtraction of human transcripts present and remaining sequences investigated 
by searching nucleotide sequence databases for homology to identify a potential pathogen. The 
advantages of this RNA sequencing are 1) no prior knowledge about the type of pathogen is required 
2) a sequence is generated for each fragment of cDNA thus allowing identification of mixed 
populations 3) RNA sequencing enables us to identify RNA viruses and RNA transcripts of bacteria, 
fungi and DNA viruses.  
Here, we describe an 8-month-old child who died of fatal astrovirus (VA1/HMO-C) 
encephalitis following a haematopoietic stem cell transplant for acute myeloid leukaemia (AML) with 
high-risk cytogenetics, t (10;11) in first remission. The diagnosis of neuroinvasive astrovirus was 
made on deep sequencing of her post-mortem brain biopsy.  
 
Case report 
The child presented with pancytopenia and hepatosplenomegaly at age of 4 months. The 
diagnosis of acute myeloid leukaemia was based on marrow studies, which indicated chromosomal 
translocation 10 and 11. She achieved remission which was consolidated using standard 
chemotherapy schedules including fludarabine, a nucleoside analogue associated with T-cell immune 
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suppression. The treatment was complicated by Enterobacter neutropenic fevers and enteritis due to 
human astrovirus (HAsV) infection, followed by persistent asymptomatic astrovirus detection in her 
stools. Since t(10;11) is associated with a high risk of disease relapse, she had a fully HLA-matched 
unrelated donor bone marrow transplant in first remission at 8 months old. She was conditioned with 
busulfan (dose was adjusted to target area under curve (AUC) at 80mg/L/h), cyclophosphamide 
(120mg/kg), melphalan (140mg/m2) and alemtuzumab (1m/kg over 5 days) and received ciclosporin 
alone for post-transplant graft-versus-host prophylaxis. The total nucleated cell dose and CD34 cell 
dose were 2.16 x 108/kg and 5.6 x 106/kg respectively. Neutrophil engraftment was demonstrated on 
Day +17 and donor chimerism was 100%. Early transplant course was complicated by severe 
mucositis, culture negative neutropenic fevers, veno-occlussive disease and grade 1 cutaneous graft-
versus-host disease that responded to topical steroid. Nutrition rehabilitation was complicated by 
protracted human astrovirus positive diarrhoea, which was finally resolved upon discharge home on 
Day +94. Her stool had been negative for astrovirus since Day +92.  Her ciclosporin was tapered off 
by Day +100 
 
The child became encephalopathic at Day+120 and subsequently developed uncontrolled dystonic 
movement. She needed ventilatory support for poor respiratory effort. There was no evidence of 
seizure activities on electroencephalogram. Cerebrospinal fluid analysis done on two occasions 
showed albuminocytoplasmic dissociation (acellular fluid with protein 1.1g/L and glucose 2.7mmol/L; 
no blast was seen on cytospin) and real-time PCR was negative for a list of comprehensive 
neutrotropenic virus (table 1), Toxoplasma gondii, 18S fungal ribosomal RNA and 16S bacterial 
ribosomal RNA. Cerebrospinal fluid culture did not yield any positive results. Repeat brain images 
indicated progressive brain volume loss, very poor myelination and high signal within bilateral basal 
ganglia (Figure 1). Brain biopsy showed scattered glial cells, increased cellularity with large reactive 
astrocytes and calcified cells, perivascular chronic inflammatory cell infiltrate and meningeal chronic 
inflammatory cell infiltrate (Figure 2). Although brain biopsy showed marked inflammatory changes, 
the extensive microbiological evaluation failed to identify any infectious causative agents for her 
encephalopathy. She received additional donor cells to accelerate immune reconstitution and her total 
(CD3-positive) T cells rose from 4 x 106/L at Day +130 to 391 x 106/L at Day +150. Despite intensive 
supportive care the child died of irreversible global brain dysfunction on Day +196. Encephalitis due to 
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Astrovirus VA1/HMO-C was diagnosed after deep sequencing of post-mortem formalin fixed paraffin 
embedded (FFPE) brain biopsy tissue. Sequencing was performed as previously described by Brown 
et al with the exception that human ribosomal RNA was excluded by ribodepletion, instead of polyA 
RNA purification, to account for the degraded RNA in FFPE tissue. Astrovirus VA1/HMO-C was 
identified by the metaMix method.(4) Sequences generated had 97–98% nucleotide identity to 
Astrovirus VA1/HMOC-London1, previously identified by Brown et al (genbank accession KJ920196). 
(5) After knowing the exact aetiology of her encephalitis, retrospective analysis of her post-mortem 
brain biopsy using AsV-Contig real-time PCR assay, which uses specific PCR primers for Astrovirus 
VA1/HMO-C, was positive.  
 
Discussion 
Our case demonstrates that the diagnosis of unexplained encephalitis in 
immunocompromised patients remains a great challenge. Neuroinvasive astrovirus (VA1/HMO-C) has 
been reported as an emerging life-threatening infection in immunocompromised hosts. Our patient is 
the fifth patient with this astrovirus encephalitis reported to date. This astrovirus belongs to VA1 and 
HMO-C group of astroviruses which are highly divergent to classical human astrovirus (HasV 1–8). 
The previous reported cases are summarized in table 2. (5-8) These patients share a number of 
similarities: 1) they are immunocompromised hosts 2) the diagnosis was only made from deep 
sequencing of brain biopsy 3) rapid progression of the illness 4) the prognosis is poor. These cases 
have highlighted that astrovirus encephalitis has multifaceted presentations, ranging from acute 
encephalopathy to chronic neurological dysfunction. The first and second reported cases presented 
with progressive cognitive impairment and motor incoordination. In addition, the clinical features can 
be bizarre and misleading to other diagnoses. Psychiatric illness was suspected in first patient for 
suicidal and homicidal ideation while third patient presented with sudden onset of sensorineural 
deafness.  
 
The diagnosis of astrovirus VA1-HMO-C encephalitis requires high index of suspicion. 
Negative human astrovirus (HasV) real-time-PCR of cerebrospinal fluid might potentially mislead. In 
fact, recent reports have shown that VA1/HMO-C astrovirus has been previously underrecognized in 
human. Burbelo et al found that high prevalence of anti-HMOAstV-C in adult healthy blood donor. Of 
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the 106 healthy adult US blood donors tested for immunoreactivity against the C-terminal capsid 
fragment of HMOAStV-C, 65% (n=69) were seropositive. (9) Similarly, this virus has been 
increasingly isolated in human stools in different countries, including Nigeria, Nepal, Pakistan, US and 
UK.  (5, 10) This virus might be asymptomatic or cause mild illnesses in immunocompetent hosts but 
it  potentially causes devastating diseases in immunocompromised patients, including encephalitis as 
reported. The mode of transmission in our patient was unclear as the child had no history of exposure 
to animals.  
 
In conclusion, our patient had two astrovirus infections, the first one being classical human 
astrovirus gastroenteritis while the second one due to a VA1/HMO-C encephalitis. Our patient and 
reported cases illustrate the value of including testing for astrovirus VA1/HMO-C in the diagnosis of 
encephalitides in immunosuppressed patients. We suggest that deep sequencing should be 
performed promptly for patients with unexplained encephalopathy as the result is available within 6 
days, allowing institution of specific therapy with intravenous immunoglobulin, antiviral therapy and 
withdrawal of immunosuppressive therapy, which potentially augment the outcome of the patients.  
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Legends for figures and tables 
 
Figure 1: MRI images on Day +120 (figure A, B, C) and Day +140 (figure D, E, F) showed progressive 
global volume loss with poor myelination. 
 
Figure 2: Brain biopsy showed scattered glial cells with pleomorphic nuclei (arrow) and perivascular 
chronic inflammatory cell infiltrate. 
 
Table 1: Reported cases of Astrovirus VA1-HMO encephalitis in the literature 
 
